RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Affiliated People's Hospital of Ningbo University; 6 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.

    Inclusion criterion 3

  3. 2. Serum direct bilirubin (DBIL)>2× upper limit of normal (ULN).

    Exclusion criterion 2

    3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3× ULN.

    Exclusion criterion 3

    4. Serum creatinine clearance rate≤30%.

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06520176, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. Patients newly diagnosed as multiple myeloma.
  • 2. Indication for ASCT.
  • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
  • 4. Life expectancy ≥ 3 months.
  • 5. Subjects must be able to understand the protocol and sign the informed consent.

Exclusion Criteria:

  • 1. Cardiac function class II or higher or cardiac ejection fraction <40%.
  • 2. Serum direct bilirubin (DBIL)>2× upper limit of normal (ULN).
  • 3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3× ULN.
  • 4. Serum creatinine clearance rate≤30%.
  • 5. Patients with active infection.
  • 6. Previously received hematopoietic stem cell mobilization.

Quoted from ClinicalTrials.gov, NCT06520176, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06520176, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06520176